Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis AG

www.novartis.com

Latest From Novartis AG

German Wellness Market News: Dr Loges Ignores EU CBD Rules, Three ‘Noo’ Brain Health Supplements

A new CBD oil from Dr Loges, three ‘nootropic’ brain health supplements from Dr Loges, Hevert and Pure Encapsulations and a magnesium supplement from Stada feature in this month’s German wellness market round-up.

Wellness Dietary Supplements

Novartis Q3 Preview: Zolgensma Back In The Spotlight

Analysts will be keen to hear about the launches of key new drugs Zolgensma and Mayzent as they ponder how long sales of Cosentyx can keep climbing.

Sales & Earnings Commercial

Galloping India Growth For Sacubitril/Valsartan Under Shadow Of Challenge

Sacubitril/valsartan combination sales surge in India driving growth in the cardiac care segment even as Novartis and challenger Natco slug it out in court over alleged patent infringement charges.

 

Commercial Strategy

Ipsen Doubles Down On FOP With Blueprint Pact

With the addition of BLU-782 to its soon-to-be filed fibrodysplasia ossificans progressiva drug palovarotene, Ipsen hopes to expand treatment options for patients with the rare bone disease.

Companies Rare Diseases
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register